Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy

References

• Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783–791. doi:10.1097/cm9.0000000000001474
   PubMed Web of Science ®Google Scholar
• Ciombor KK, Berlin J. Targeting metastatic colorectal cancer - present and emerging treatment options. Pharmgenomics Pers Med. 2014;7:137–144. doi:10.2147/pgpm.s47582
   PubMedGoogle Scholar
• Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–685. doi:10.1001/jama.2021.0106
   PubMed Web of Science ®Google Scholar
• Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378(13):1177–1188. doi:10.1056/NEJMoa1713709
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Yamanaka T, Shiozawa M, et al. Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized Phase III ACHIEVE-2 trial. Ann Oncol. 2021;32(1):77–84. doi:10.1016/j.annonc.2020.10.480
   PubMed Web of Science ®Google Scholar
• Dasari A, Morris VK, Allegra CJ, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020;17(12):757–770. doi:10.1038/s41571-020-0392-0
   PubMed Web of Science ®Google Scholar
• Osumi H, Shinozaki E, Yamaguchi K, Zembutsu H. Clinical utility of circulating tumor DNA for colorectal cancer. Cancer Sci. 2019;110(4):1148–1155. doi:10.1111/cas.13972
   PubMed Web of Science ®Google Scholar
• Hamaguchi R, Tsuchiya T, Miyata G, et al. Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, Phase II trial (JORTC-CAM03). Support Care Cancer. 2020;28(8):3649–3657. doi:10.1007/s00520-019-05205-1
   PubMed Web of Science ®Google Scholar
• Yang L, Sun Y, Huang XE, et al. Carcinoma microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for stage II rectal cancer. Asian Pac J Cancer Prev. 2015;16(4):1545–1551. doi:10.7314/apjcp.2015.16.4.1545
   PubMedGoogle Scholar
• Lam SW, Guchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev. 2016;50:9–22. doi:10.1016/j.ctrv.2016.08.001
   PubMed Web of Science ®Google Scholar
• Mitselou A, Ioachim E, Skoufi U, et al. Predictive role of thymidine phosphorylase expression in patients with colorectal cancer and its association with angiogenesis-related proteins and extracellular matrix components. In vivo. 2012;26(6):1057–1067.
   PubMed Web of Science ®Google Scholar
• Won HS, Lee MA, Chung ES, et al. Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer. BMC Cancer. 2010;10:564. doi:10.1186/1471-2407-10-564
   PubMed Web of Science ®Google Scholar
• Amatori F, Di Paolo A, Del Tacca M, et al. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. Pharmacogenet Genomics. 2006;16(11):809–816. doi:10.1097/01.fpc.0000230410.07899.bc
   PubMed Web of Science ®Google Scholar
• Du YB, Zhang TF, Cui K, et al. TYMP基因遗传变异对R0切除术后的结直肠癌患者接受辅助化疗的疗效及安全性的影响 [The influence of Thymidine Phosphorylase genetic variation on clinical outcomes and safety of colorectal cancer patients received adjuvant chemotherapy after R0 resection]. Zhonghua Yi Xue Za Zhi. 2018;98(32):2569–2573. Chinese. doi:10.3760/cma.j.issn.0376-2491.2018.32.007
   PubMedGoogle Scholar
• Huang L, Chen F, Chen Y, et al. Thymidine phosphorylase gene variant, platelet counts and survival in gastrointestinal cancer patients treated by fluoropyrimidines. Sci Rep. 2014;4:5697. doi:10.1038/srep05697
   PubMed Web of Science ®Google Scholar
• Chen WC, Wu G, Zhang W, et al. 卡培他滨方案在胃癌辅助化疗中的疗效及相关药物基因组学分析 [Clinical outcomes of gastric cancer patients received capecitabine based adjuvant chemotherapy and the corresponding pharmacogenomics analysis]. Zhonghua Yi Xue Za Zhi. 2018;98(42):3420–3425. Chinese. doi:10.3760/cma.j.issn.0376-2491.2018.42.009
   PubMedGoogle Scholar
• Yang H, Wang H, Wang J, et al. Multiplex single-nucleotide polymorphism genotyping by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Biochem. 2003;314(1):54–62. doi:10.1016/s0003-2697(02)00641-3
   PubMed Web of Science ®Google Scholar
• Song ZZ, Zhao LF, Zuo J, et al. Clinical outcomes and safety of apatinib mesylate in the treatment of advanced non-squamous non-small cell lung cancer in patients who progressed after standard therapy and analysis of the KDR gene polymorphism. Onco Targets Ther. 2020;13:603–613. doi:10.2147/ott.s222985
   PubMed Web of Science ®Google Scholar
• Zhang Y, Song J, Zhao Z, et al. Single-cell transcriptome analysis reveals tumor immune microenvironment heterogenicity and granulocytes enrichment in colorectal cancer liver metastases. Cancer Lett. 2020;470:84–94. doi:10.1016/j.canlet.2019.10.016
   PubMed Web of Science ®Google Scholar
• Malla SB, Fisher DJ, Domingo E, et al. In-depth clinical and biological exploration of DNA damage immune response as a biomarker for oxaliplatin use in colorectal cancer. Clin Cancer Res. 2021;27(1):288–300. doi:10.1158/1078-0432.ccr-20-3237
   PubMed Web of Science ®Google Scholar
• Reece M, Saluja H, Hollington P, et al. The use of circulating tumor DNA to monitor and predict response to treatment in colorectal cancer. Front Genet. 2019;10:1118. doi:10.3389/fgene.2019.01118
   PubMed Web of Science ®Google Scholar
• Su J, Dai B, Yuan W, et al. The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study. Cancer Chemother Pharmacol. 2020;85(5):969–978. doi:10.1007/s00280-020-04069-1
   PubMed Web of Science ®Google Scholar
• Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 2019;5(12):1710–1717. doi:10.1001/jamaoncol.2019.3616
   PubMed Web of Science ®Google Scholar
• Li AJ, Li HG, Tang EJ, et al. PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients. World J Gastroenterol. 2018;24(5):631–640. doi:10.3748/wjg.v24.i5.631
   PubMed Web of Science ®Google Scholar
• Ogunwobi OO, Mahmood F, Akingboye A. Biomarkers in colorectal cancer: current research and future prospects. Int J Mol Sci. 2020;21(15):5311. doi:10.3390/ijms21155311
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol. 2015;33(32):3733–3740. doi:10.1200/jco.2015.60.9107
   PubMed Web of Science ®Google Scholar
• Yang J, Xu H, Guo X, et al. Pretreatment inflammatory indexes as prognostic predictors for survival in colorectal cancer patients receiving neoadjuvant chemoradiotherapy. Sci Rep. 2018;8(1):3044. doi:10.1038/s41598-018-21093-7
   PubMed Web of Science ®Google Scholar
• Iveson TJ, Sobrero AF, Yoshino T, et al. Duration of adjuvant doublet chemotherapy (3 or 6 months) in patients with high-risk stage II colorectal cancer. J Clin Oncol. 2021;39(6):631–641. doi:10.1200/jco.20.01330
   PubMed Web of Science ®Google Scholar
• de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57(10):1229–1254. doi:10.1007/s40262-018-0644-7
   PubMed Web of Science ®Google Scholar
• Jennings BA, Loke YK, Skinner J, et al. Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PLoS One. 2013;8(10):e78053. doi:10.1371/journal.pone.0078053
   PubMed Web of Science ®Google Scholar
• Zhang DY, Yuan XQ, Yan H, et al. Association between DCK 35708 T>C variation and clinical outcomes of acute myeloid leukemia in South Chinese patients. Pharmacogenomics. 2016;17(14):1519–1531. doi:10.2217/pgs-2016-0084
   PubMed Web of Science ®Google Scholar
• Fariña-Sarasqueta A, van Lijnschoten G, Rutten HJ, van den Brule AJ. Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study. Cancer Chemother Pharmacol. 2010;66(6):1167–1171. doi:10.1007/s00280-010-1403-0
   PubMed Web of Science ®Google Scholar
• Yan Z, Gu YY, Hu XD, et al. Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism. Oncol Lett. 2020;20(3):3035–3045. doi:10.3892/ol.2020.11857
   PubMed Web of Science ®Google Scholar
• Marangoni E, Laurent C, Coussy F, et al. Capecitabine efficacy is correlated with TYMP and RB1 expression in PDX established from triple-negative breast cancers. Clin Cancer Res. 2018;24(11):2605–2615. doi:10.1158/1078-0432.ccr-17-3490
   PubMed Web of Science ®Google Scholar
• Lu M, Gao J, Wang XC, Shen L. Expressions of thymidylate synthase, thymidine phosphorylase, class III beta-tubulin, and excision repair cross-complementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin. Chin J Cancer Res. 2011;23(4):288–294. doi:10.1007/s11670-011-0288-8
   PubMed Web of Science ®Google Scholar
• Huang X, Wang L, Chen Y, Zheng X, Wang X. Poor prognosis associated with high levels of thymidine phosphorylase and thrombocytosis in patients with renal cell carcinoma. Urol Int. 2017;98(2):162–168. doi:10.1159/000448483
   PubMed Web of Science ®Google Scholar
• Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev. 2009;29(6):903–953. doi:10.1002/med.20159
   PubMed Web of Science ®Google Scholar